Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective
Background: Substance abuse leads to blood-brain barrier dysfunction and activation of neuro-inflammatory pathways. However, the contribution of serum levels of Toll-like receptor 2 (TLR-2) and S100 calcium-binding protein B (S100B) to neuropsychological outcomes has not been clearly established. Th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shaheed Beheshti University of Medical Sciences
2025-01-01
|
| Series: | International Journal of Medical Toxicology and Forensic Medicine |
| Subjects: | |
| Online Access: | https://journals.sbmu.ac.ir/ijmtfm/article/view/44049/34382 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849397049489883136 |
|---|---|
| author | Babak Mostafazadeh Mahtab Ramezani Leila Simani Shahin Shadnia Fatemeh Abbaszadeh Peyman Erfantalab Evini Somayeh Monjazeb Mitra Rahimi Hossein Pakdaman Faezeh Maghsudloo |
| author_facet | Babak Mostafazadeh Mahtab Ramezani Leila Simani Shahin Shadnia Fatemeh Abbaszadeh Peyman Erfantalab Evini Somayeh Monjazeb Mitra Rahimi Hossein Pakdaman Faezeh Maghsudloo |
| author_sort | Babak Mostafazadeh |
| collection | DOAJ |
| description | Background: Substance abuse leads to blood-brain barrier dysfunction and activation of neuro-inflammatory pathways. However, the contribution of serum levels of Toll-like receptor 2 (TLR-2) and S100 calcium-binding protein B (S100B) to neuropsychological outcomes has not been clearly established. This study aims to explore the relationship between TLR-2 and S100B serum concentrations in individuals with substance abuse and their potential influence on neuropsychological results, specifically regarding the functioning of the frontal lobe.
Methods: This study involved 28 individuals who were diagnosed with substance abuse at Loghman Hakim Hospital’s Toxicology Unit in 2022. Serum TLR-2 concentration and S100B levels, as neuroinflammatory markers, and the frontal assessment battery (FAB), as executive function markers, were measured.
Results: Substance abuse patients exhibited elevated levels of both TLR-2 and S100B. In drug addicts, a strong positive relationship was detected between serum levels of TLR-2 and S100B (r=0.742, P=0.0021) levels. Nevertheless, no significant relationship was found between FAB scores and serum concentrations of S100B and TLR-2.
Conclusion: This study reveals increased serum TLR-2 and S100B levels in individuals with substance abuse. However, these elevated levels did not appear to be associated with risk factors related to substance abuse or frontal lobe function. |
| format | Article |
| id | doaj-art-1319758b2f2e4b33984bf504f60bb393 |
| institution | Kabale University |
| issn | 2251-8762 2251-8770 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Shaheed Beheshti University of Medical Sciences |
| record_format | Article |
| series | International Journal of Medical Toxicology and Forensic Medicine |
| spelling | doaj-art-1319758b2f2e4b33984bf504f60bb3932025-08-20T03:39:10ZengShaheed Beheshti University of Medical SciencesInternational Journal of Medical Toxicology and Forensic Medicine2251-87622251-87702025-01-01151Serum TLR2 and S100B in Substance Abuse: A Clinical PerspectiveBabak MostafazadehMahtab RamezaniLeila SimaniShahin ShadniaFatemeh AbbaszadehPeyman Erfantalab EviniSomayeh MonjazebMitra RahimiHossein PakdamanFaezeh MaghsudlooBackground: Substance abuse leads to blood-brain barrier dysfunction and activation of neuro-inflammatory pathways. However, the contribution of serum levels of Toll-like receptor 2 (TLR-2) and S100 calcium-binding protein B (S100B) to neuropsychological outcomes has not been clearly established. This study aims to explore the relationship between TLR-2 and S100B serum concentrations in individuals with substance abuse and their potential influence on neuropsychological results, specifically regarding the functioning of the frontal lobe. Methods: This study involved 28 individuals who were diagnosed with substance abuse at Loghman Hakim Hospital’s Toxicology Unit in 2022. Serum TLR-2 concentration and S100B levels, as neuroinflammatory markers, and the frontal assessment battery (FAB), as executive function markers, were measured. Results: Substance abuse patients exhibited elevated levels of both TLR-2 and S100B. In drug addicts, a strong positive relationship was detected between serum levels of TLR-2 and S100B (r=0.742, P=0.0021) levels. Nevertheless, no significant relationship was found between FAB scores and serum concentrations of S100B and TLR-2. Conclusion: This study reveals increased serum TLR-2 and S100B levels in individuals with substance abuse. However, these elevated levels did not appear to be associated with risk factors related to substance abuse or frontal lobe function.https://journals.sbmu.ac.ir/ijmtfm/article/view/44049/34382substance abusetoll-like receptor 2 (tlr-2)s100 calcium-binding protein b (s100b)executive function |
| spellingShingle | Babak Mostafazadeh Mahtab Ramezani Leila Simani Shahin Shadnia Fatemeh Abbaszadeh Peyman Erfantalab Evini Somayeh Monjazeb Mitra Rahimi Hossein Pakdaman Faezeh Maghsudloo Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective International Journal of Medical Toxicology and Forensic Medicine substance abuse toll-like receptor 2 (tlr-2) s100 calcium-binding protein b (s100b) executive function |
| title | Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective |
| title_full | Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective |
| title_fullStr | Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective |
| title_full_unstemmed | Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective |
| title_short | Serum TLR2 and S100B in Substance Abuse: A Clinical Perspective |
| title_sort | serum tlr2 and s100b in substance abuse a clinical perspective |
| topic | substance abuse toll-like receptor 2 (tlr-2) s100 calcium-binding protein b (s100b) executive function |
| url | https://journals.sbmu.ac.ir/ijmtfm/article/view/44049/34382 |
| work_keys_str_mv | AT babakmostafazadeh serumtlr2ands100binsubstanceabuseaclinicalperspective AT mahtabramezani serumtlr2ands100binsubstanceabuseaclinicalperspective AT leilasimani serumtlr2ands100binsubstanceabuseaclinicalperspective AT shahinshadnia serumtlr2ands100binsubstanceabuseaclinicalperspective AT fatemehabbaszadeh serumtlr2ands100binsubstanceabuseaclinicalperspective AT peymanerfantalabevini serumtlr2ands100binsubstanceabuseaclinicalperspective AT somayehmonjazeb serumtlr2ands100binsubstanceabuseaclinicalperspective AT mitrarahimi serumtlr2ands100binsubstanceabuseaclinicalperspective AT hosseinpakdaman serumtlr2ands100binsubstanceabuseaclinicalperspective AT faezehmaghsudloo serumtlr2ands100binsubstanceabuseaclinicalperspective |